Twist Bioscience Showcases Next-Generation Sequencing Solutions at the 2019 Advances in Genome Biology and Technology Meeting

— New Features Enable Sample to Sequencer in a Single Day –

— Customer Presentations Demonstrate Benefit of Twist NGS Solutions in
Neurology, Direct-to-Consumer Testing, Hereditary Disease and Liquid
Biopsy –

SAN FRANCISCO–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#DNAlt;/agt;–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, today announced the availability of new
product solutions for its Twist Human Core Exome Kit and Twist Custom
Panels next-generation sequencing (NGS) target enrichment workflows,
allowing customers to move from sample to sequencer in a single day.
Twist will showcase these new features at the 2019 Advances in Genome
Biology and Technology (AGBT) meeting from February 28, 2019 to March 2,
2019 in Florida. During the meeting, several customers will demonstrate
their use of Twist’s NGS library preparation and target enrichment
solutions for a wide variety of applications.

“Our customers consistently dive deep to explore genetic variability and
uncover disease-causing mutations, elucidating biology and studying
pathways involved in disease,” said Emily M. Leproust, Ph.D., CEO and
co-founder of Twist Bioscience. “Our NGS products provide uniform
amplification and coverage of target sequences, lowering the overall
sequencing costs as confirmed by many customers. By continuously
innovating our product line to meet evolving research needs, we believe
our products can enable the full range of healthcare applications, from
surveillance to identification to monitoring.”

New Products for Twist Human Core Exome Kit and Twist Custom Panels

Twist’s enhanced NGS target enrichment product line, available to Early
Access customers, can offer dramatic time savings by accelerating
hybridization to as little as 15 minutes, is designed to seamlessly
integrate into any automation workflow and is compatible with Covaris
fragmentation for FFPE and other highly-degraded samples. In addition,
Twist’s quality management systems governing the design and manufacture
of its NGS Target Enrichment Panels received ISO 9001:2015 and
13485:2016 certification, allowing Twist to support customers in more
regulated markets that require this certification.

New products include Twist Fast Hybridization and Wash Kit, Twist
Universal Blockers to allow flexible blocking and improved on-target
capture; the Twist Universal Adapter System, to maximize performance for
library preparation; and, the Twist Mechanical Fragmentation Library
Prep Kit for highly-degraded samples.

Presentations at AGBT

On Friday, March 1, 2019, in addition to a keynote from Dr. Leproust,
customers from several institutions will demonstrate the power of using
the Twist NGS Target Enrichment Solutions to identify neurological and
inherited diseases, quickly scale direct-to-consumer DNA testing, and
the development of liquid (blood) biopsies.

  • Brendan Blumenstiel of the Broad Institute of MIT and Harvard will
    give a presentation titled ‘Leveraging custom deep targeted sequencing
    for low allele fraction variant detection in cfDNA and challenging
    sample types’
  • Regina Pellegrino, Ph.D. of Children’s Hospital of Philadelphia will
    provide insight on ‘High-efficiency neurological panel design using
    Twist Bioscience double-stranded custom target enrichment probes and
    capture optimization for aged dry blood spot samples’
  • William Lee, Ph.D. of Helix will give a talk on ‘Design and
    optimization of an enhanced medical exome’
  • Pertteli Salmenperä, Ph.D. of Blueprint Genetics will detail
    ‘Evaluation of a custom inherited diseases panel for clinical

For more information, or to attend the session, please visit:
Posters will be available on the Twist website here.

Poster Presentations

Also on March 1, 2019, researchers from Twist will present two posters:

  • Data-Driven Improvements in NGS Target Enrichment Performance
    [Abstract #512]
  • Development of a High-Throughput Target Enrichment System [Abstract

About the Twist NGS Target Enrichment Solutions

Applying its proprietary silicon-based DNA synthesis platform, Twist
Bioscience manufactures double-stranded DNA (dsDNA) that is then
incorporated into sample preparation products for customers performing
next-generation sequencing experiments and analysis. Because Twist is
able to apply its custom oligonucleotide pools to precisely target,
extract, and uniformly amplify the target DNA segments, its NGS target
enrichment solutions considerably improve the accuracy of the downstream
sequencing analysis. This enables customers to perform fewer sequencing
runs per sample, without sacrificing accuracy, saving them time and
money. The Twist Human Core Exome Kit includes all the tools needed for
library construction, target capture and enrichment to prepare a sample
for sequencing. This product suite is designed to provide exceptional
performance, maximum capture efficiency and the flexibility to customize
kit configuration. Twist Bioscience believes it is the only company to
offer double-stranded DNA (dsDNA) probes within a comprehensive target
enrichment kit used for exome and targeted sequencing. Using dsDNA as
opposed to single-stranded DNA captures all specified sequences
uniformly and avoids the problem of deamination (removal of an amino
group). Deamination interferes with the accurate detection of gene
mutations, and may hinder genetic results and clinical diagnoses,
particularly in cancer and ancient samples. For more information please

The Human Core Exome Complete Kit is indicated for Research Use Only.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist make
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.

Follow us on Twitter
| Facebook
| LinkedIn
| YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, Twist Bioscience’s enhanced NGS product solutions and
related dramatic time savings. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors that
may cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and uncertainties
of rapidly changing technologies and extensive competition in synthetic
biology could make the products Twist Bioscience is developing obsolete
or non-competitive; uncertainties of the retention of a significant
customer; risks of third party claims alleging infringement of patents
and proprietary rights or seeking to invalidate Twist Bioscience’s
patents or proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies. For
a further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s business in
general, see Twist Bioscience’s risk factors set forth in Twist
Bioscience’s Annual Report on Form 10-K filed with the Securities and
Exchange Commission on December 20, 2018 and Twist Bioscience’s Form
10-Q for the quarter ended December 31, 2018 filed with the Securities
and Exchange Commission on February 11, 2019. Any forward-looking
statements contained in this press release speak only as of the date
hereof, and Twist Bioscience specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.


Investor Contact:
Argot Partners
Maeve Conneighton

Media Contact:
Angela Bitting

error: Content is protected !!